Aadi Bioscience Inc (NAS:AADI)

$ 1.405 0.005 (0.36%) Market Cap: 34.50 Mil Enterprise Value: -52.73 Mil PE Ratio: 0 PB Ratio: 0.38 GF Score: 30/100

Q1 2024 Aadi Bioscience Inc Earnings Call Transcript
May 08, 2024

$1.84 (-12.80%)

Earnings
Q4 2023 Aadi Bioscience Inc Earnings Call Transcript
Mar 13, 2024

$2.16 (+11.34%)

Earnings
Aadi Bioscience Inc Investor Conferece Call Transcript
Dec 14, 2023
Aadi Bioscience Inc at Jefferies London Healthcare Conference Transcript
Nov 14, 2023
Q3 2023 Aadi Bioscience Inc Earnings Call Transcript
Nov 08, 2023

$4.65 (-3.53%)

Earnings
Aadi Bioscience Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2023
Q2 2023 Aadi Bioscience Inc Earnings Call Transcript
Aug 09, 2023

$5.44 (-6.85%)

Earnings
Aadi Bioscience Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Aadi Bioscience Inc at TD Cowen Oncology Innovation Summit (Virtual) Transcript
May 30, 2023
Q1 2023 Aadi Bioscience Inc Earnings Call Transcript
May 10, 2023

$7.08 (-16.61%)

Earnings
Q4 2022 Aadi Bioscience Inc Earnings Call Transcript
Mar 28, 2023

$6.85 (-5.52%)

Earnings
Q3 2022 Aadi Bioscience Inc Earnings Call Transcript
Nov 09, 2022

$13.41 (+2.84%)

Earnings
Aadi Bioscience Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 14, 2022
Q2 2022 Aadi Bioscience Inc Earnings Call Transcript
Aug 10, 2022

$13.88 (-1.49%)

Earnings
Q1 2022 Aadi Bioscience Inc Earnings Call Transcript
May 12, 2022

$12.65 (+9.33%)

Earnings
Aadi Bioscience Inc FYARRO Corporate Call Transcript
Nov 23, 2021
Aadi Bioscience Inc at H C Wainwright Precision Oncology Conference (Virtual) Transcript
Oct 20, 2021
Q3 2020 Aerpio Pharmaceuticals Inc Earnings Call Transcript
Nov 10, 2020

Earnings
Q2 2020 Aerpio Pharmaceuticals Inc Earnings Call Transcript
Aug 12, 2020

Earnings
Aerpio Pharmaceuticals Inc Annual Shareholders Meeting Transcript
Jun 24, 2020
Aerpio Pharmaceuticals, Inc. - Special Call Transcript
Jun 12, 2020
Q4 2019 Aerpio Pharmaceuticals Inc Earnings Call Transcript
Mar 16, 2020

Earnings
Aerpio Pharmaceuticals, Inc. to Discuss the Results from the TIME-2b Study Conference Call Transcript
Mar 18, 2019
Q4 2018 Aerpio Pharmaceuticals Inc Earnings Call Transcript
Mar 05, 2019

Earnings

Aadi Bioscience Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2023 / 01:30PM GMT

Release Date Price: $6.05 (+1.51%)

Transcript

Frank Tang

Good morning, everyone. I am Frank Chang from the Morgan Stanley Investment Banking team. And before we get started, I have to quickly read the following disclaimer. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

So I'm pleased today to be joined on stage with Interim CEO and CFO of Aadi Biosciences, Scott Giacobello. Welcome, Scott.

Scott M. Giacobello

Aadi Bioscience, Inc. - Interim CEO, President, CFO & Treasurer

Great. Thanks, Frank. It's great to be here.

Questions & Answers

Frank Tang;Scott M. Giacobello

Aadi

To kick things off, Scott, would you like to spend a few minutes kind of at the beginning to give us an overview of Aadi's financial status, cash position, runway and recent progress?

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.